iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q4FY23 Review: Torrent Pharma: Resilient performance on top line & margins

21 Mar 2024 , 05:46 PM

Torrent’s execution in the Branded Generic (BGx) markets remains robust, with its organic India/Brazil business growing 15/17% cc YoY in Q4 and Ebitda margins expanding 50bps QoQ to 29.6%. Lowdouble-digit growth is expected to sustain in Torrent’s India portfolio driven by 2-3% volume growth, 7% price hikes and increasing contribution from new launches, while Brazil business will also benefit from 6 planned product launches in FY24. Analysts of IIFL securities believe there are further levers for Torrent’s continued margin expansion trajectory given the price-hike-led growth in BGx markets, further improvement in India productivity on margin scale-up in Curatio, and cost optimisation efforts to improve margin profile of the US business.

India business expected to outperform IPM growth by 200bps p.a.: 

Torrent’s India business (ex-Curatio) grew 15% YoY in Q4 and 13% in FY23, while the acquired Curatio portfolio grew 19% YoY in Q4. With Curatio’s Ebitda margins already improving 400-500bps (vs pre-acquisition margins of 26-27%), Torrent’s overall India PCPM will continue to improve from depressed levels of Rs7.8lakhs per month in H2FY23 (vs Rs9.8lakhs in FY22), particularly since the organic India portfolio is also expected to sustain 12-13% revenue Cagr over FY23-26.

Working on cost optimisation to improve margin profile of US biz: 

Although analysts of IIFL Securities expect Torrent’s US sales to decline 5% cc in FY24, FY25 could see a potential recovery as product approvals are expected to restart from Dahej plant (2 ‘483 observations recently) over next 6-7 months and Torrent will also be launching 3-4 products p.a. from partner CMO facilities (incl. Revlimid in FY25). Additionally, 2-3 Oncology launches p.a. are being targeted from the new Oncology plant. However, Indrad plant will require re-inspection before WL can be lifted.

Margin guidance of 60-100bps expansion p.a. appears conservative, given the price-led growth in India/Brazil, improving PCPM for the expanded rep team in India, and potential recovery in the US business from FY25. Analysts of IIFL Securities assume Torrent’s Ebitda margins to expand 170bps over FY23-24 to 31%, but there remains an upside risk to their estimates.

Related Tags

  • Torrent Pharma
  • Torrent Pharma Q4
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
29 Mar 2024   |   10:14 AM
Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.